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Introduction
• Colorectal cancer is the fourth most common cancer in 
North America
• Second leading cause of cancer death in North America
• Annually, approximately 53,000 people die of colorectal 
cancer
• It is largely preventable through screening. 
Aim statement
• Our aim was to increase the amount of colon cancer screening 
in the OU internal Medicine clinic by 10% by April, 2020.
• Project was initiated in September of 2019 – 7 months to reach 
goal
Methods
• All patients seen in the OU Internal Medicine clinic were 
screened for eligibility for colon cancer screening using the 
USPSTF criteria.
• If the patients were eligible they were offered several screening 
possibilities to include colonoscopy, FIT testing, and Cologuard
screening.
• The necessary means to undergo testing was then arranged for 
eligible patients. 
Methods
• First PDSA cycle: consisted of drafting a standardized letter which was 
added to the clinic EMR.
• Allowed patients to bring a guest with them via SoonerRide to their 
colonoscopy appointments
• Providers and nurses were educated 
• Unfortunately with the onset of the SARS- CoV2 pandemic only one 
PDSA cycle was implemented 
Data collection
Graph 1: The percentage of patients out of total qualifying patients in the OU IM clinic who have documented colon cancer screening done or reason why deferred. The goal for meaningful use 
is 70%.
Results
• Following the implementation of the first PDSA cycle the percentage 
of patients out of total qualifying patients in the OU IM clinic who 
have documented colon cancer screening done or had reason why 
deferred remained at 65.1%. 
• There were no significant increases or decreases in the total 
percentage.
• Following the onset of the COVID-19 pandemic, the percentage 
decreased to as low as 62.7%. 
Conclusion
• There was neither a significant increase or decrease in colon cancer 
screening in the five months following implementation of the first 
PDSA cycle. 
• A dramatic decrease following the onset of COVID-19 pandemic was 
observed due to lack of office visits, and elective procedures
Discussion
• In March 2020 the American Cancer society recommended that all 
routine (nondiagnostic) cancer screenings be suspended in the wake 
of the COVID-19 pandemic.
• As a result, screening rates decreased by 86% relative to the 
average before January 2020. 
• A focus on FIT like testing may be beneficial moving forward to 
reduce rates of missed cancers. 
Questions
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